Myda Advisors LLC Lian Bio Transaction History

Myda Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.33 - $4.6 $133,000 - $459,999	-100,000 Reduced 50.0%	100,000 $447,000
Q3 2023 Nov 14, 2023	BUY	$1.49 - $2.46 $92,602 - $152,886	62,149 Added 45.08%	200,000 $298,000
Q2 2023 Aug 11, 2023	BUY	$1.79 - $2.85 $31,953 - $50,875	17,851 Added 14.88%	137,851 $314,000
Q1 2023 May 12, 2023	SELL	$1.57 - $2.66 $23,550 - $39,900	-15,000 Reduced 11.11%	120,000 $235,000
Q4 2022 Feb 13, 2023	BUY	$1.14 - $2.11 $17,100 - $31,649	15,000 Added 12.5%	135,000 $221,000
Q2 2022 Aug 12, 2022	BUY	$2.15 - $6.01 $73,100 - $204,340	34,000 Added 39.53%	120,000 $259,000
Q1 2022 May 13, 2022	BUY	$2.8 - $6.21 $184,800 - $409,860	66,000 Added 330.0%	86,000 $319,000
Q4 2021 Feb 11, 2022	BUY	$6.14 - $16.2 $122,800 - $324,000	20,000 New	20,000 $123,000

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $31.4M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Myda Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Myda Advisors LLC with notifications on news.